GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Aug 19, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 19, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-repurchase, stock-buyback
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on August 19, 2025, that it purchased a certain number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — The company making the share repurchase.
- Merrill Lynch International (company) — The corporate stockbroker acting on behalf of GSK plc for the share repurchase.
- August 2025 (date) — The reporting period for the transaction.
- 20250819 (date) — The date of the filing and the transaction.
FAQ
What was the specific number of GSK plc ordinary shares purchased?
The filing states that a 'certain number' of ordinary shares were purchased, but the exact quantity is not specified in the provided text.
What was the total dollar amount spent on the share repurchases?
The filing does not disclose the total dollar amount spent on the purchase of GSK plc's ordinary shares.
On what date did the share repurchase transactions occur?
The filing indicates the transactions occurred during the month of August 2025, with the filing date being August 19, 2025.
Who acted as GSK plc's corporate stockbroker for these transactions?
Merrill Lynch International acted as GSK plc's corporate stockbroker for these transactions.
What is the par value of GSK plc's ordinary shares?
The ordinary shares of GSK plc have a par value of 31¼ pence each.
Filing Stats: 2,918 words · 12 min read · ~10 pages · Grade level 3.4 · Accepted 2025-08-19 06:15:40
Filing Documents
- a7948v.htm (6-K) — 4279KB
- 0001654954-25-009782.txt ( ) — 4280KB
From the Filing
IN OWN SHARES a7948v       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of August 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each. Date of purchase:   18 August 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   221,293   Lowest price paid per share (GBp):   1,433.00p   Highest price paid per share (GBp):   1,443.00p   Volume-weighted average price paid per share (GBp):   1,437.72p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 24,364,286 ordinary shares.   Following the above purchase, the Company will hold 242,498,669 ordinary shares in treasury and have 4,072,893,065 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,072,893,065. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   5.95 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:        GSK plc (ISIN: GB00BN7SWP63) Date of purchases:       18 August 2025   Investment firm:          Merrill Lynch International     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   221,293   1,443.00p   1,433.00p   1,437.72p   CBOE ( CHIX)   0   -   -   -   CBOE ( BATE)   0   -   -   -       Individual transactions:   Number ofShares   Price per Share (GBp)   Tradingvenue   Date oftransaction   Time oftransaction   Transaction reference number   167   1,438.50    XLON   18-Aug-2025   08:00:27   0XL061000000000034JFKH   11   1,438.00    XLON   18-Aug-2025   08:01:07   0XL061100000000034JG5P   11   1,438.00    XLON   18-Aug-2025   08:01:07   0XL064000000000034JG0B   12   1,438.00    XLON   18-Aug-2025   08:01:07   0XL061000000000034JFOU   12   1,438.00    XLON   18-Aug-2025   08:01:07   0XL061000000000034JFOV   12   1,438.00    XLON   18-Aug-2025   08:01:07   0XL061100000000034JG5O   12   1,438.00    XLON   18-Aug-2025   08:01:07   0XL061700000000034JG8J   12   1,438.00    XLON   18-Aug-2025